C

Chabiotech Co Ltd
KOSDAQ:085660

Watchlist Manager
Chabiotech Co Ltd
KOSDAQ:085660
Watchlist
Price: 10 740 KRW -27.73%
Market Cap: 604.8B KRW
Have any thoughts about
Chabiotech Co Ltd?
Write Note

Chabiotech Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Chabiotech Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
C
Chabiotech Co Ltd
KOSDAQ:085660
Net Income (Common)
-â‚©2.6B
CAGR 3-Years
54%
CAGR 5-Years
N/A
CAGR 10-Years
14%
No Stocks Found

Chabiotech Co Ltd
Glance View

Market Cap
604.8B KRW
Industry
Health Care

Cha Biotech Co., Ltd. engages in the research of cell therapy and storage of cord blood. The company is headquartered in Seoul, Seoul. The company went IPO on 2005-12-27. is a Korea-based company mainly engaged in the bio business. Along with its subsidiaries, the Company operates its business through two segments: bio segment and optical segment. Its bio segment engages in the provision of medical services; development of stem cells and cell therapy products; production of cosmetics and cosmetic raw materials; distribution of medical devices and others, as well as cord blood storage, health care services and others. Its optical segment engages in the manufacture of optical lenses, optical modules and other parts, which are used in mobile phone cameras.

Intrinsic Value
9 965.82 KRW
Overvaluation 7%
Intrinsic Value
Price
C

See Also

What is Chabiotech Co Ltd's Net Income (Common)?
Net Income (Common)
-2.6B KRW

Based on the financial report for Sep 30, 2024, Chabiotech Co Ltd's Net Income (Common) amounts to -2.6B KRW.

What is Chabiotech Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
14%

Over the last year, the Net Income (Common) growth was 90%. The average annual Net Income (Common) growth rates for Chabiotech Co Ltd have been 54% over the past three years , and 14% over the past ten years .

Back to Top